Evidence map›Paper›PMID 35745345›Full record

ArticleNanomaterials (Basel, Switzerland)2022

Hansen Solubility Parameter Analysis on Dispersion of Oleylamine-Capped Silver Nanoinks and their Sintered Film Morphology.

Satoshi Saita, Shin-Ichi Takeda, Hideya Kawasaki

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Satoshi SaitaDepartment of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, Kansai University, Osaka 564-8680, Japan.
Shin-Ichi TakedaTakeda Colloid Techno-Consulting Co., Ltd., Osaka 564-0051, Japan.
Hideya KawasakiDepartment of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, Kansai University, Osaka 564-8680, Japan.ORCID 0000-0003-2713-2057

Funding

Japan Society for the Promotion of Science 20K21095 and 22H01915
6 · The paper itself

Abstract

Optimizing stabilizers and solvents is crucial for obtaining highly dispersed nanoparticle inks. Generally, nonpolar (hydrophobic) ligand-stabilized nanoparticles show superior dispersibility in nonpolar solvents, whereas polar ligand (hydrophilic)-stabilized nanoparticles exhibit high dispersibility in polar solvents. However, these properties are too qualitative to select optimum stabilizers and solvents for stable nanoparticle inks, and researchers often rely on their experiences. This study presents a Hansen solubility parameter (HSP)-based analysis of the dispersibility of oleylamine-capped silver nanoparticle (OAm-Ag NP) inks for optimizing ink preparation. We determined the HSP sphere of the OAm-Ag NPs, defined as the center coordinate, and the interaction radius in 3D HSP space. The solvent's HSP inside the HSP sphere causes high dispersibility of the OAm-Ag NPs in the solvent. In contrast, the HSPs outside the sphere resulted in low dispersibility in the solvent. Thus, we can quantitatively predict the dispersibility of the OAm-Ag NPs in a given solvent using the HSP approach. Moreover, the HSP sphere method can establish a correlation between the dispersibility of the particles in inks and the sintered film morphology, facilitating electronic application of the nanoparticle inks. The HSP method is also helpful for optimizing stabilizers and solvents for stable nanoparticle inks in printed electronics.

Indexed as

Ag nanoparticlesdispersibilityHansen solubility parameternanoinkoleylamineprinted electronics

Identifiers

PMID35745345
PMCPMC9230637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.